Despite $30-40 billion in GenAI investment, 95% of organizations see zero measurable return. New MIT research reveals a stark "GenAI Divide" between the 5% achieving results and the majority stuck in pilot purgatory.

For AML teams, GenAI represents unprecedented opportunity. The potential for reduced false positives, faster investigations, and streamlined compliance workflows is within reach for organizations that approach AI strategically.

The successful 5% start with regulatory readiness, not technical capabilities. They demand adaptive systems within established governance and focus on specific, measurable use cases. With early adopters establishing competitive advantages, the window for strategic positioning is narrowing.